Moderna (MRNA) closed at $34.01 in the latest trading session, marking a -1.9% move from the prior day. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

Moderna’s stock has experienced a significant decline of 12.90% over the past week, reflecting investor concerns about the company’s recent financial performance and future prospects.

An explosive phase of growth may be ahead thanks to several potential product launches. A lot can happen in 10 years, and that's good news for a struggling stock like Moderna (NASDAQ: MRNA).

Moderna’s stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the ...

That surely came as a relief to Moderna investors, since the company's latest stock-rattling news was its withdrawal of a Food and Drug Administration application for a combination COVID-19/flu ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about MRNA stock here.